We previously reported that the pVHL‐atypical PKC‐JunB pathway contributed to promote the cell invasiveness and to enhance angiogenesis in ccRCC in a HIF‐independent manner, and we also showed that CCL2 was one of the downstream effectors of JunB by microarray analysis 6. This evidence concerns the gene CCL2 and nonpapillary renal cell carcinoma.